Immutep secures US patent for efti combination therapies
IMMP•Immutep received a US patent covering eftilagimod alfa combinations with PD-1 pathway inhibitors, bringing its US patent holdings in the family to five. Protection expires March 23, 2038, including 806 days of patent term adjustment.
1. Patent protection
Immutep received a US patent covering combinations of eftilagimod alfa, or efti, with PD-1 pathway inhibitors. The grant brings its US patent holdings in the family to five; protection expires March 23, 2038, including 806 days of patent term adjustment. Immutep also filed a continuation application to pursue additional embodiments of the invention.
